@mnewland99
My Whipple was in 2016. I don't think it was standard then to provide information about genetic mutations. I did order genetic tests outside my HMO, and all I remember is that the results did not point to any changes in my therapy.
In my case, neoadjuvant chemo -- Abraxane and gemcitabine -- was very important. It reduced my CA 19-9 from 1300 to around 20. It was only ordered because I was borderline for the surgery.
I remember asking the surgeon how much of the pancreas he had removed; he said he didn't know as he would have to weigh it. At first I only used about one third of the dosage of Creon prescribed for me so I must assume I still had some functioning pancreas after the surgery. Now, at age 82, I think the remaining pancreas is producing less enzymes. (I have read that the typical Whipple removes about 50% of the pancreas.)

My pathology report states the specimen is "well differentiated" (good news) with "focal extra pancreatic extension" (not good news).

I had four months of neoadjuvant chemo with abraxane and Gemzar; after the surgery I had six months almost all only Gemzar.

I consulted an academic oncologist, now a full professor at the University of California. He said Metformin might help me one day -- I never pursued this, but you can look it up.

Good luck!

CG